R. Yee

发表

Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model

D. Morton, M. Kelley, S. Stern, 1996, Annals of Surgical Oncology.

Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.

W. Ye, D. Morton, R. Essner, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Humoral I mmune R esponse t o a T herapeutic P olyvalent C ancer Vaccine A fter C omplete R esection o f T hick P rimary M elanoma and S entinel L ymphadenectomy

W. Ye, D. Morton, R. Essner, 2003 .

Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma.

R. Gupta, D. Morton, M. Kelley, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor-Associated A ntigen T A90 I mmune C omplex A ssay Predicts R ecurrence a nd S urvival A fter S urgical T reatment of S tage I -III M elanoma

D. Morton, M. Kelley, E. Hsueh, 2001 .

Tumor‐associated antigen TA‐90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma

D. Morton, L. Wanek, M. Kelley, 1998, Cancer.

Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy

C. Shikuma, L. Ndhlovu, L. M. Gangcuangco, 2019, HIV research & clinical practice.

A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck.

P. Citrin, K. Dasmahapatra, G. Hill, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma?

D. Morton, E. Hsueh, K. Qi, 2000, Annals of Surgical Oncology.

A Comparison of 3 Tumor Markers (MIA, TA90IC, S100B) in Stage III Melanoma Patients

D. Elashoff, D. Morton, X. Ye, 2007, Cancer investigation.

Serum TA90 immune complex assay can predict outcome after resection of thick (≥4 mm) primary melanoma and sentinel lymphadenectomy

W. Ye, D. Morton, R. Essner, 2002, Annals of Surgical Oncology.

Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors.

W. Ye, D. Morton, L. Wanek, 2004, Journal of the American College of Surgeons.

Preoperative serum TA90-IC as an adjunct to serum CA 19-9 in the diagnosis of pancreatic malignancy: a pilot study.

W. Ye, D. Morton, A. Bilchik, 2002, Current surgery.

CancerVax, An Allogeneic Tumor Cell Vaccine, Induces Specific Humoral and Cellular Immune Responses in Advanced Colon Cancer

R. Elashoff, W. Ye, D. Morton, 2001, Annals of Surgical Oncology.

Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma.

R. Gupta, D. Morton, E. Hsueh, 1998, Journal of the American College of Surgeons.

TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.

R. Gupta, D. Morton, E. Hsueh, 1997, The cancer journal from Scientific American.